Phase 1
The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerate…
Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in RelapseMyelodysplastic Syndrome Acute Myeloid Leukemia